Clinical Trial

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07078500
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: The Second Affiliated Hospital of Jiaxing University, Taizhou First People's Hospital, Huzhou Central Hospital, Zhejiang Cancer Hospital, Dongyang People's Hospital, Yuyao People's Hospital, Taizhou Hospital, Shaoxing Central Hospital, Affiliated Hospital of Jiaxing University, Shaoxing People's Hospital, The Central Hospital of Lishui City, Second Affiliated Hospital of Wenzhou Medical University, Ningbo People's Hospital, The People's Hospital of Quzhou, Zhuji People's Hospital of Zhejiang Province, First People's Hospital of Hangzhou
Conditions Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment 48 participants
Start Date 2025-05-05
Primary Completion 2026-10-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-19